NSAID Safety Data Merit No Further Action, EMEA Committee Says
This article was originally published in The Pink Sheet Daily
Executive Summary
However, the Committee for Medicinal Products for Human Use recommends consistent labeling at the national level.
You may also be interested in...
Celebrex Label Adds Cardiovascular Risk Language
Celecoxib labeling revision includes long-term safety data from three celecoxib trials, one of which suggests increased cardiovascular risk. Celebrex also gains ankylosing spondylitis indication.
EMEA Gives Pfizer One Year To Provide Data For Bextra Reintroduction
European Medicines Agency concludes its review of the COX-2 class with formal recommendation to remove Bextra from the market and additional contraindications and warnings for class labeling. The agency will now turn its attention to the safety profile of “some conventional” NSAIDs.
COX-2 Inhibitors Contraindicated For Heart Disease Patients In Europe
European Medicines Agency says COX-2 inhibitors should not be used in individuals with ischemic heart disease or stroke and recommends caution when prescribing the drugs for patients with risk factors for heart disease. Agency also adds a hypertension contraindication for Merck’s Arcoxia.